Christina N. Cordeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christina N. Cordeiro has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Mindy S. Christianson
Reproductive Endocrinology & Infertility Section, Obstetrics and Gynecology Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
4 shared publications Mindy S. Christianson
Division of Reproductive Endocrinology and Infertility, Johns Hopkins University School of Medicine, MD, USA
3 shared publicationsColleen M. McCarthy
2 shared publications- James H. Segars
Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women’s Health Research, Johns Hopkins Medicine, Baltimore, MD 21205, USA
2 shared publications - Mary L. Gemignani
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications Alex Clarke
1 shared publication
Latest Publications
- 9 August 2021
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 38 (10) , 2713-2721
Predictive factors for fertility preservation in pediatric and adolescent girls with planned gonadotoxic treatment
Purpose To characterize female pediatric and adolescent patients seen for fertility preservation consultation at an academic medical center and to describe the association between demographic or clinical factors and the use of fertility preservation treatment (FPT). Methods This is a retrospective chart analysis of female pediatric and adolescent patients seen for fertility preservation consultation at an academic fertility center over a 14-year period from 2005 to 2019. Results One hundred six females aged 3–21 years were seen for fertility preservation consultation with a mean age of 16.6 years. Diagnoses included hematologic malignancies (41.5%), gynecologic malignancies (9.4%), other malignancies (31.1%), non-malignant hematologic disease (14.2%), and non-malignant conditions (3.8%). Overall, 64.2% of subjects pursued fertility preservation, including oocyte cryopreservation (35.8%) and ovarian tissue cryopreservation (23.6%). Overall, age, minority race, diagnosis, time since diagnosis, and median household income were not significantly associated with odds of completing an FPT procedure. Among all patients, those who underwent gonadotoxic therapy prior to consultation had a lower odds of receiving FPT (OR= 0.24, 95% CI 0.10–0.55). Among patients without chemotherapy exposure, no factors were associated with FPT. Conclusions Among pediatric and adolescent patients at an academic center undergoing a fertility preservation consultation, there were no socioeconomic or clinical barriers to FPT use in those who had not yet undergone gonadotoxic therapy. The only factor that was negatively associated with odds of pursuing FPT was prior chemotherapy exposure.
- 9 August 2021
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 38 (10) , 2713-2721
Predictive factors for fertility preservation in pediatric and adolescent girls with planned gonadotoxic treatment
Purpose To characterize female pediatric and adolescent patients seen for fertility preservation consultation at an academic medical center and to describe the association between demographic or clinical factors and the use of fertility preservation treatment (FPT). Methods This is a retrospective chart analysis of female pediatric and adolescent patients seen for fertility preservation consultation at an academic fertility center over a 14-year period from 2005 to 2019. Results One hundred six females aged 3–21 years were seen for fertility preservation consultation with a mean age of 16.6 years. Diagnoses included hematologic malignancies (41.5%), gynecologic malignancies (9.4%), other malignancies (31.1%), non-malignant hematologic disease (14.2%), and non-malignant conditions (3.8%). Overall, 64.2% of subjects pursued fertility preservation, including oocyte cryopreservation (35.8%) and ovarian tissue cryopreservation (23.6%). Overall, age, minority race, diagnosis, time since diagnosis, and median household income were not significantly associated with odds of completing an FPT procedure. Among all patients, those who underwent gonadotoxic therapy prior to consultation had a lower odds of receiving FPT (OR= 0.24, 95% CI 0.10–0.55). Among patients without chemotherapy exposure, no factors were associated with FPT. Conclusions Among pediatric and adolescent patients at an academic center undergoing a fertility preservation consultation, there were no socioeconomic or clinical barriers to FPT use in those who had not yet undergone gonadotoxic therapy. The only factor that was negatively associated with odds of pursuing FPT was prior chemotherapy exposure.
- 1 May 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (5) , 101930
Conservatively treated endometrial intraepithelial neoplasia/cancer: Risk of intrauterine synechiae
- 1 May 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (5) , 101930
Conservatively treated endometrial intraepithelial neoplasia/cancer: Risk of intrauterine synechiae
- 17 August 2020
- Published by Wiley in American Journal of Hematology
- Vol. 98 (11) , 1819
Withdrawal: “Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost‐effective.” Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. Lanzkron, Mindy S. Christianson, Lydia H. Pecker
For couples with sickle cell trait (SCT) who are at risk for having a child with sickle cell disease (SCD), cost is a barrier to using in vitro fertilization (IVF) with preimplantation genetic testing for monogenic diseases (PGT‐M) and insurance coverage is not universal. The objective of this study was to evaluate the cost‐effectiveness of IVF+PGT‐M for couples who both carry SCT and wish to avoid SCD in a child compared to natural conception with the possible birth of a child with SCD, and the associated lifetime medical costs and lost income. A cost‐effectiveness analysis was performed with a decision analytic model. Sensitivity analyses, including Monte Carlo Simulations, assessed the impact of changes in input parameters on the incremental cost‐effectiveness ratio (ICER). Probabilities and cost estimates were derived from the published literature. Effectiveness was measured in life years (LY) gained. The ICER was calculated to determine the cost‐effectiveness of the IVF+PGT‐M intervention. Compared to natural conception, IVF+PGT‐M had an effectiveness gain of 30 LY, an additional cost of $572,392.68 per individual conceived, and an ICER of $19,319 per LY gained. The ICER is lower than a conservative, preset willingness to pay (WTP) threshold of $50,000 per LY gained. Monte Carlo Simulations demonstrated that, in 91% of iterations, IVF+PGT‐M was cost‐effective at the WTP of $50,000. IVF+PGT‐M is a cost‐effective strategy to avoid conceiving a child with SCD and broader insurance coverage is warranted.
- 17 August 2020
- Published by Wiley in American Journal of Hematology
- Vol. 98 (11) , 1819
Withdrawal: “Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost‐effective.” Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. Lanzkron, Mindy S. Christianson, Lydia H. Pecker
For couples with sickle cell trait (SCT) who are at risk for having a child with sickle cell disease (SCD), cost is a barrier to using in vitro fertilization (IVF) with preimplantation genetic testing for monogenic diseases (PGT‐M) and insurance coverage is not universal. The objective of this study was to evaluate the cost‐effectiveness of IVF+PGT‐M for couples who both carry SCT and wish to avoid SCD in a child compared to natural conception with the possible birth of a child with SCD, and the associated lifetime medical costs and lost income. A cost‐effectiveness analysis was performed with a decision analytic model. Sensitivity analyses, including Monte Carlo Simulations, assessed the impact of changes in input parameters on the incremental cost‐effectiveness ratio (ICER). Probabilities and cost estimates were derived from the published literature. Effectiveness was measured in life years (LY) gained. The ICER was calculated to determine the cost‐effectiveness of the IVF+PGT‐M intervention. Compared to natural conception, IVF+PGT‐M had an effectiveness gain of 30 LY, an additional cost of $572,392.68 per individual conceived, and an ICER of $19,319 per LY gained. The ICER is lower than a conservative, preset willingness to pay (WTP) threshold of $50,000 per LY gained. Monte Carlo Simulations demonstrated that, in 91% of iterations, IVF+PGT‐M was cost‐effective at the WTP of $50,000. IVF+PGT‐M is a cost‐effective strategy to avoid conceiving a child with SCD and broader insurance coverage is warranted.
- 1 August 2020
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 9 (4) , 502-507
Understanding Patients' Knowledge and Feelings Regarding Their Cryopreserved Ovarian Tissue: A Qualitative Interviewing Study
Purpose: For prepubertal girls, or when gonadotoxic treatment is urgent, ovarian tissue cryopreservation (OTC) represents the only option for fertility preservation. We sought to determine patients' knowledge and feelings about their cryopreserved ovarian tissue. Methods: We conducted qualitative interviews with women aged 18 years or older who underwent OTC at our academic fertility center between 2006 and 2017. Subjects were recruited by phone and participated in a single telephone interview using a standardized guide. Interviews were performed until data saturation was reached. Atlas.ti software was used for content analysis. Results: We interviewed eight women with a mean age of 25.8 ± 6.1 years (range, 19–37 years). The mean age at OTC was 20.4 ± 7.5 years (range, 13–35 years). Indications for fertility preservation included hematologic cancer/disease (4/8) or gynecological cancer/BRCA2 positive (4/8). Most patients (7/8) desired future fertility. Although half of the interviewees understood the OTC procedure, only two knew that the tissue can be used for future fertility and only one was aware of the benefits for vasomotor symptoms. Five subjects expressed positive emotions regarding OTC; one felt angry that the decision was made by her parents and two were concerned that OTC might not have been a good choice. However, most subjects (5/8) expressed a desire to better understand OTC and most (5/8) wished for more education about it. Conclusion: This study identifies a significant knowledge gap among patients with cryopreserved ovarian tissue about its uses and benefits as well as a strong desire among these women for improved education about this fertility preservation modality.
- 1 August 2020
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 9 (4) , 502-507
Understanding Patients' Knowledge and Feelings Regarding Their Cryopreserved Ovarian Tissue: A Qualitative Interviewing Study
Purpose: For prepubertal girls, or when gonadotoxic treatment is urgent, ovarian tissue cryopreservation (OTC) represents the only option for fertility preservation. We sought to determine patients' knowledge and feelings about their cryopreserved ovarian tissue. Methods: We conducted qualitative interviews with women aged 18 years or older who underwent OTC at our academic fertility center between 2006 and 2017. Subjects were recruited by phone and participated in a single telephone interview using a standardized guide. Interviews were performed until data saturation was reached. Atlas.ti software was used for content analysis. Results: We interviewed eight women with a mean age of 25.8 ± 6.1 years (range, 19–37 years). The mean age at OTC was 20.4 ± 7.5 years (range, 13–35 years). Indications for fertility preservation included hematologic cancer/disease (4/8) or gynecological cancer/BRCA2 positive (4/8). Most patients (7/8) desired future fertility. Although half of the interviewees understood the OTC procedure, only two knew that the tissue can be used for future fertility and only one was aware of the benefits for vasomotor symptoms. Five subjects expressed positive emotions regarding OTC; one felt angry that the decision was made by her parents and two were concerned that OTC might not have been a good choice. However, most subjects (5/8) expressed a desire to better understand OTC and most (5/8) wished for more education about it. Conclusion: This study identifies a significant knowledge gap among patients with cryopreserved ovarian tissue about its uses and benefits as well as a strong desire among these women for improved education about this fertility preservation modality.
- 24 March 2020
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 37 (5) , 1037-1055
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis
Purpose Twelve percent of women in the USA will develop invasive breast cancer in their lifetime, and that risk increases to 80% if they carry a BRCA1 or BRCA2 mutation. BRCA1/2 mutations are thought to potentially affect ovarian reserve and/or fertility. Methods PubMed and PubMed Central were searched for publications on ovarian reserve–related outcomes (i.e., AMH and response to controlled ovarian hyperstimulation (COH) protocols) that were reported in relation to BRCA1 and/or BRCA2 mutations from 1950 through May 2019. A meta-analysis was conducted to create forest plots and summary effect measures using Review Manager 5.3. Results This article reviews the 16 qualifying publications. There were several fundamental methodological differences in the study designs and outcome details reported in AMH studies. Summary statistics found no difference in AMH levels between BRCA1/2+ women as compared with controls (Z overall test effects p ≥ 0.45). Regarding responses to COH, there were overall non-significantly fewer total and mature numbers of oocytes retrieved in BRCA1/2+ cases as compared with controls (meta-analysis Z overall test effects p ≥ 0.40). Conclusions While the summary measures indicate no significant differences in AMH levels between BRCA1/2+ cases and controls, readers should be aware that there are significant methodological differences in the AMH reports. Additionally, the response to COH protocols does not seem to be significantly lower in BRCA1/2 mutation carriers in the existing literature. Continued research on both of these clinical parameters would be beneficial for patient counseling.
- 24 March 2020
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 37 (5) , 1037-1055
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis
Purpose Twelve percent of women in the USA will develop invasive breast cancer in their lifetime, and that risk increases to 80% if they carry a BRCA1 or BRCA2 mutation. BRCA1/2 mutations are thought to potentially affect ovarian reserve and/or fertility. Methods PubMed and PubMed Central were searched for publications on ovarian reserve–related outcomes (i.e., AMH and response to controlled ovarian hyperstimulation (COH) protocols) that were reported in relation to BRCA1 and/or BRCA2 mutations from 1950 through May 2019. A meta-analysis was conducted to create forest plots and summary effect measures using Review Manager 5.3. Results This article reviews the 16 qualifying publications. There were several fundamental methodological differences in the study designs and outcome details reported in AMH studies. Summary statistics found no difference in AMH levels between BRCA1/2+ women as compared with controls (Z overall test effects p ≥ 0.45). Regarding responses to COH, there were overall non-significantly fewer total and mature numbers of oocytes retrieved in BRCA1/2+ cases as compared with controls (meta-analysis Z overall test effects p ≥ 0.40). Conclusions While the summary measures indicate no significant differences in AMH levels between BRCA1/2+ cases and controls, readers should be aware that there are significant methodological differences in the AMH reports. Additionally, the response to COH protocols does not seem to be significantly lower in BRCA1/2 mutation carriers in the existing literature. Continued research on both of these clinical parameters would be beneficial for patient counseling.
- Open Access
- 1 March 2019
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2019 (4) , hoz019
Patients’ preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks
The process of deciding whether to pursue preimplantation genetic testing (PGT) of an embryo is highly stressful for individuals and couples and has adverse emotional consequences (e.g. distress and uncertainty). PGT influences patients’ lives in both positive and negative ways and is experienced at an individual level, as a dyadic unit, as a family member and as part of the society. Here, we argue that providing a conceptual framework with which to understand the `experience of decision making’ about PGT for monogenic disease (PGT-M) testing specifically, as well as the factors contributing to `decisional distress’ and `uncertainty’ that patients endure as a result—apart from what decision they make—is crucial to optimizing patient counseling, satisfaction and outcomes in the field of ART. Derived from psychological theory, the framework proposed here identifies three categories of contributing factors to decisional distress and uncertainty in considering PGT-M; namely, ‘intraindividual’, ‘interpersonal’ and ‘situational’ factors. We reviewed evidence from the PGT literature to inform our framework. Well-accepted theories of stress and health decision making were also reviewed for their relevance to PGT-M decision making, focusing on potential distress and uncertainty. Our novel conceptual framework can be used to inform clinical practice, to advance research and to aid the development of interventions for individuals and couples who are deciding whether or not to use PGT-M. Alleviating emotional distress and uncertainty can improve patients’ well-being during their reproductive journey.
- 1 March 2019
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2019 (4) , hoz019
Open AccessPatients’ preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks
The process of deciding whether to pursue preimplantation genetic testing (PGT) of an embryo is highly stressful for individuals and couples and has adverse emotional consequences (e.g. distress and uncertainty). PGT influences patients’ lives in both positive and negative ways and is experienced at an individual level, as a dyadic unit, as a family member and as part of the society. Here, we argue that providing a conceptual framework with which to understand the `experience of decision making’ about PGT for monogenic disease (PGT-M) testing specifically, as well as the factors contributing to `decisional distress’ and `uncertainty’ that patients endure as a result—apart from what decision they make—is crucial to optimizing patient counseling, satisfaction and outcomes in the field of ART. Derived from psychological theory, the framework proposed here identifies three categories of contributing factors to decisional distress and uncertainty in considering PGT-M; namely, ‘intraindividual’, ‘interpersonal’ and ‘situational’ factors. We reviewed evidence from the PGT literature to inform our framework. Well-accepted theories of stress and health decision making were also reviewed for their relevance to PGT-M decision making, focusing on potential distress and uncertainty. Our novel conceptual framework can be used to inform clinical practice, to advance research and to aid the development of interventions for individuals and couples who are deciding whether or not to use PGT-M. Alleviating emotional distress and uncertainty can improve patients’ well-being during their reproductive journey.
- Open Access
- 1 May 2018
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 24, 48-50
Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening
- 1 May 2018
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 24, 48-50
Open AccessAdvanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening
- 1 June 2017
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 29 (3) , 175-179
Zika virus and assisted reproduction
Due to the fact that the Zika virus can be sexually transmitted, there is a potential risk for disease transmission at several stages of assisted reproduction. Such a possibility poses a serious challenge to couples pursing fertility with reproductive technologies. Here, we discuss what is known regarding Zika virus infection with respect to sexual transmission and correlate this knowledge with recent recommendations in the realm of infertility treatment. Zika virus can be transmitted from infected men and women through vaginal, oral or anal intercourse. Zika virus RNA has been detected in blood, semen, cervical mucus and vaginal fluid. Currently, the Centers for Disease Control recommends that infected men wait 6 months, and infected women 8 weeks, prior to attempting pregnancy. Reproductive tissue donors should wait 6 months before giving a specimen. Further study of Zika virus transmission in different reproductive tissues and establishment of validated testing methods for viral disease transmissibility are urgently needed. Reproductive technologists need to establish screening, testing and laboratory protocols aimed to reduce the risk of Zika virus transmission during assisted reproduction.
- 1 June 2017
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 29 (3) , 175-179
Zika virus and assisted reproduction
Due to the fact that the Zika virus can be sexually transmitted, there is a potential risk for disease transmission at several stages of assisted reproduction. Such a possibility poses a serious challenge to couples pursing fertility with reproductive technologies. Here, we discuss what is known regarding Zika virus infection with respect to sexual transmission and correlate this knowledge with recent recommendations in the realm of infertility treatment. Zika virus can be transmitted from infected men and women through vaginal, oral or anal intercourse. Zika virus RNA has been detected in blood, semen, cervical mucus and vaginal fluid. Currently, the Centers for Disease Control recommends that infected men wait 6 months, and infected women 8 weeks, prior to attempting pregnancy. Reproductive tissue donors should wait 6 months before giving a specimen. Further study of Zika virus transmission in different reproductive tissues and establishment of validated testing methods for viral disease transmissibility are urgently needed. Reproductive technologists need to establish screening, testing and laboratory protocols aimed to reduce the risk of Zika virus transmission during assisted reproduction.
- 1 March 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (3) , 184-193
Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety
Importance: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. Objectives: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes. Evidence Acquisition: A detailed literature review was performed on PubMed. Results: The treatment of gynecologic malignancies during pregnancy mirrors that outside pregnancy, with a balance between maternal versus fetal health. Fertility-sparing surgery can be offered to stage IA2 and low-risk IB1 cervical, stage I epithelial ovarian, germ cell ovarian, or sex-cord stromal ovarian tumors. Delayed treatment can be offered for stage IB1 cervical cancer. Neoadjuvant and/or adjuvant chemotherapy can be given for advanced gynecologic cancers with good disease-free survival without significant adverse neonatal outcomes. Conclusions: A multidisciplinary approach and improved education of providers regarding the surgical and chemotherapeutic treatments in pregnancy are needed in order to fully inform patients regarding treatment options. Further research in women who are pregnant is needed to determine the safety of diagnostic and therapeutic procedures used in the nonpregnant woman. Relevance: This article reviews and supports treatment of gynecologic cancer during pregnancy, calls for additional study and long-term follow-up, and justifies improved education of patients and providers regarding treatment options. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: After completing this activity, the learner should be better able to (1) review general principles in the management and treatment of gynecologic cancers in pregnancy, (2) review the diagnosis and treatment of cervical cancer in pregnancy, and (3) review the diagnosis and treatment of ovarian cancer in pregnancy.
- 1 March 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (3) , 184-193
Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety
Importance: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. Objectives: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes. Evidence Acquisition: A detailed literature review was performed on PubMed. Results: The treatment of gynecologic malignancies during pregnancy mirrors that outside pregnancy, with a balance between maternal versus fetal health. Fertility-sparing surgery can be offered to stage IA2 and low-risk IB1 cervical, stage I epithelial ovarian, germ cell ovarian, or sex-cord stromal ovarian tumors. Delayed treatment can be offered for stage IB1 cervical cancer. Neoadjuvant and/or adjuvant chemotherapy can be given for advanced gynecologic cancers with good disease-free survival without significant adverse neonatal outcomes. Conclusions: A multidisciplinary approach and improved education of providers regarding the surgical and chemotherapeutic treatments in pregnancy are needed in order to fully inform patients regarding treatment options. Further research in women who are pregnant is needed to determine the safety of diagnostic and therapeutic procedures used in the nonpregnant woman. Relevance: This article reviews and supports treatment of gynecologic cancer during pregnancy, calls for additional study and long-term follow-up, and justifies improved education of patients and providers regarding treatment options. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: After completing this activity, the learner should be better able to (1) review general principles in the management and treatment of gynecologic cancers in pregnancy, (2) review the diagnosis and treatment of cervical cancer in pregnancy, and (3) review the diagnosis and treatment of ovarian cancer in pregnancy.
- Open Access
- 13 February 2017
- Published by Hindawi Limited in The Breast Journal
- Vol. 23 (2) , 200-205
Breast Cancer in Pregnancy: Avoiding Fetal Harm When Maternal Treatment Is Necessary
The management of breast cancer during pregnancy poses unique challenges and requires a multi‐disciplinary approach. In this review, we discuss the treatment of breast cancer in pregnancy and recent updates regarding the safety of surgical and chemotherapeutic treatments, including both oncologic and fetal outcomes. The treatment of breast cancer during pregnancy mirrors that outside of pregnancy, with a few important differences dictated by the balance of maternal versus fetal health. Overall, surgical treatment, neo‐adjuvant chemotherapy, and/or adjuvant chemotherapy are feasible in most women during pregnancy. Further research to determine the safety of these therapies in pregnancy‐associated breast cancer is warranted.
- 13 February 2017
- Published by Hindawi Limited in The Breast Journal
- Vol. 23 (2) , 200-205
Open AccessBreast Cancer in Pregnancy: Avoiding Fetal Harm When Maternal Treatment Is Necessary
The management of breast cancer during pregnancy poses unique challenges and requires a multi‐disciplinary approach. In this review, we discuss the treatment of breast cancer in pregnancy and recent updates regarding the safety of surgical and chemotherapeutic treatments, including both oncologic and fetal outcomes. The treatment of breast cancer during pregnancy mirrors that outside of pregnancy, with a few important differences dictated by the balance of maternal versus fetal health. Overall, surgical treatment, neo‐adjuvant chemotherapy, and/or adjuvant chemotherapy are feasible in most women during pregnancy. Further research to determine the safety of these therapies in pregnancy‐associated breast cancer is warranted.